Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Which healthcare stock can dividend investors safely buy? Let's consider two excellent options: AbbVie (NYSE: ABBV) and Amgen ...

The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity. The Health Care Select Sector ...

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...

A native of De Pere, Wisconsin, Kinziger is considered a four-star recruit by 247Sports, On3 and ESPN. 247Sports ranks the ...

Adial's PK study satisfied an FDA requirement for the AD04 Phase 3 trial. Study confirmed AD04 can be taken with or without ...

Vivek Ramaswamy reacted to a list of unnecessary government expenditures that included $33 million of government expenditure to run 'Monkey Island' in South Carolina; $549K to a Russian lab ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...